The nation of Zimbabwe has declined a significant American health deal valued at $367m (272 million pounds) spanning five years due to the United States' insistence on confidential information.
The decision came to light following a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa believed the agreement was "skewed".
An official representative later explained that the US was requesting biological samples for scientific study and profit while was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the challenging and unfortunate process of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the United States had donated more than $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has appealed for continued negotiations to secure a deal suitable to all parties so the nation's critical HIV programme can be sustained.
Wider Background
Zimbabwe's decision comes after a similar situation in neighbouring Kenya, where a high court blocked a related deal with the US following concerns were raised about the safety of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen aid for the US government, but Trump stated its spending was "inefficient" and his administration was seeking government-to-government agreements to enhance transparency and accountability.
According to statements, Sixteen African countries have to date signed these new health pacts, constituting more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation might have yielded significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving HIV treatment via US-supported initiatives," Tremont said.
However, government spokesperson Nick Mangwana said the proposed deal was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no corresponding guarantee of benefiting from any medical innovations – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our nation would provide the raw materials for scientific discovery with no certainty that the end products would be accessible to our population if a new disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the US's withdrawal from the global health body and its push of one-on-one deals were undermining structures already established via the global health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme created to manage future pandemics.
"This framework is intended to guarantee that when a country contributes its samples, the resulting advantages – such as medicines and cures – are shared equitably, not commercialised solely by those with the funds to develop them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued dialogue with our US partners on how subsequent collaboration might be structured in a way that honours the independence and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but urged that talks need to persist given that much of the nation's Aids initiatives relied on external financing.
"If technical issues exist, including those involving data governance or agreement terms, these can often be addressed through technical clarification and mutually agreed protections," the group added.
The situation underscores the complex debate between receiving vital foreign assistance and safeguarding local interests in an increasingly data-driven world.